Clinician-scientists have the training and motivation to translate basic science into tools for improved clinical care, but the road to achieve this is hardly straight forward, particularly for large scale genomic datasets. is year's Joe Doupe Young Investigator award winner, Dr. Torsten Nielsen, details successful examples of new scienti c insights, diagnostics and clinical trials that have resulted from microarray-based gene expression pro ling of sarcomas: TLE1 as a biomarker for synovial sarcoma, histone deacetylase inhibitor therapy for translocation-associated sarcomas of young adults, and CSF1 pathway inhibitors for tenosynovial giant cell tumors. Results from exciting, emerging next generation sequencing technologies will need to undergo similar validation and preclinical studies before they can be expected to impact patient care.
e year 2000 was full of excitement in the clinical research community, arising from the development of new microarray technologies that promised an entirely new and comprehensive view of the molecular biology of human disease. In many ways, the recent application of these next generation sequencing technologies to medical research has generated similar anticipation that major clinical breakthroughs are just around the corner. Clinician-scientists realize, however, that the actual clinical implementation of such basic science and discoverybased research is another matter entirely, requiring years of research and development, most of which are ultimately unsuccessful in changing clinical practice. e path is rarely direct or clear, requiring multiple steps not only in the science itself, but also in obtaining the training, funding, personnel, infrastructure and (what may be most di cult of all for clinicianinvestigators) time to organize and achieve these steps. In this article, I will relate the story of how a discovery research project I started as a resident eventually led to multi-institutional implementation of a new diagnostic test, and to two cancertargeted therapy clinical trials that began accruing patients in autumn 2010.
Clinician-scientist training and research
I trained in the McGill MD/PhD program, but the key benets of combined medical and scienti c training can also be achieved by many other routes, including separate degrees, research-intensive residencies, clinician-investigator programs, and fellowship training. Clinical training confers a diverse knowledge and perspective on human disease, an understanding of the clinical thinking and decision-making process (including such mantras as rst-do-no-harm, focus on diseases that are common and/or dangerous and/or xable, and "if it doesn't change your management, don't order the test"), and an appreciation of the realities of patient care and clinical implementation of new technologies and ideas. Serious research training drives home the principles of proper experimental design (e.g., a positive result is meaningless without a negative control), imparts credibility as a researcher, develops practical skills in the writing and critical appraisal of papers and grants, provides plenty of experience in dealing with failure, and gives the trainee some extra time to observe mentors and role models before making critical decisions about what specialty to pursue and where to do it.
My inspiration as a child came from Terry Fox; I knew early on that I wanted to become a cancer researcher whose work would actually help people. Although I had not originally considered pathology, I came to realize that the day-to-day work in this specialty o en concerns cancer. e pathology profession o ers access to vital tissue resources, relative control over my time, and places me squarely at the forefront of translational research because molecular biology advances translate most directly into diagnostics and biomarkers, relative to comparatively long timelines for drug development. For other diseases, di erent specialty choices might provide a better match between research and clinic. e UBC Anatomical Pathology program I joined had the additional advantage of o ering large amounts of elective time for research.
Following the release of " e Chipping Forecast" special issue of Nature Genetics, detailing the impending microarray revolution [1] , many researchers thought these new techniques might replace the traditional pathology techniques [2] . I was fortunate enough to do a research elective in England, in a laboratory developing and implementing its own microarray technology. Although this research time was productive [3, 4] , I quickly realized that experience was more important than equipment when it came to generating reliable results. Pat Brown at Stanford was one of the pioneers of cDNA microarray technology, and, with colleagues, had begun to apply these high throughput techniques to neoplastic diseases, leading to breakthroughs in lymphoma [5] and breast cancer [6] , among others. By having credible credentials and by asking the right questions, I was able to transform a brief visit to California into a collaborative research project that quickly led to the world's rst large scale expression pro ling study of so tissue tumors [7] . is also exposed me to tissue microarrays [8] , a new, complementary technology that opened up huge possibilities for translational studies that were easier to do in Canada than in the USA [9] .
Among the key lessons I learned from these experiences during residency was the necessity of having both tissue specimens and linked patient data resources in order to perform e ective translational research. Although new and exciting, few molecular tests could actually beat established clinical tools such as microscopic morphology. Time was the single most important resource to have, and I was able to leverage the successful residency research program into a short fellowship period to hone clinical subspecialty skills in a low volume, high interest area (sarcomas), and to write up my rst grant applications, which secured an academic position with protected research time.
frequently large tumors, diagnostically challenging (encompassing nearly 100 subtypes), and, for the most part, they lack e ective systemic treatment options. Nevertheless, sarcomas have a fascinating molecular biology that is highly favourable for translation into new clinical tools for diagnosis and treatment [10] . Our expression pro ling studies [7, 11] had helped crystallize the concept that nearly half of sarcomas have a wellde ned molecular oncogenesis, o en driven by speci c point mutations or translocations. c-kit tyrosine kinase activating mutations had been shown to drive the biology of gastrointestinal stromal tumors [12] , leading to the rst e ective drug therapy (imatinib) for this sarcoma [13, 14] . I hoped to work toward similar advances for other sarcomas where such breakthroughs had yet to be made.
Among so tissue sarcomas with a de ned underlying molecular event, synovial sarcoma is the most common. is disease typically occurs in the limbs of young adults, and long term survival rates are disappointing (about 50%) due to the propensity for early and late metastases that are incurable with conventional chemotherapy [15] . Synovial sarcoma is characterized by a pathognomonic t(X;18)(p11;q11) event, fusing (a chromatin remodeling protein associated with the SWI-SNF complex and transcriptional activation) to an SSX gene (which interacts with Polycomb proteins, leading to chromatin condensation and gene silencing) [16] . e net effect on transcription was unknown, nor were any inhibitors of SS18 or SSX available.
In 2003, the research strategy for my new laboratory was to draw on expression pro le data to identify key pathways, induced by SS18-SSX, that might be targeted by existing drugs never before tested in this disease. Immediately evident in the pro le were genes involved in body segment patterning and mesenchymal di erentiation, including retinoid-response genes [7, 17, 18] . ese were of particular interest due to the breakthrough of retinoic acid-based di erentiation therapy for promyelocytic leukemia [19] , which also bears a fusiontranscription factor translocation (PML-RARα). Although chemical and pharmaceutical retinoids were readily available for testing, it took well over a year for me to hire personnel, sta and equip my rst lab, secure approvals and appropriate disease models, arrange materials transfer agreements, and generate results ... which all proved negative! My hypothesis was wrong. Neither retinoid agonists nor antagonists had signicant e ects on synovial sarcoma cell growth or death.
e value of the back-up plan Fortunately my training in research and in grantsmanship had taught me at least two important things: each tested hypothesis should have a back up plan in place in case it is wrong, and the research program should encompass multiple aims that are not dependent on each other's success. In leukemia, retinoid resistance can be overcome through the actions of histone deacetylase (HDAC) inhibitors, which, when tested by ourselves and others, appeared highly e ective in synovial sarcoma preclinical models [20] . HDAC inhibitors are an emerging class of drugs that reverse epigenetic changes, frequently leading to reactivation of gene expression [21, 22] .
Concurrent aims to develop diagnostic tools for synovial sarcoma using tissue microarrays were making signi cant progress [23, 24] , identifying TLE1 as the most sensitive and speci c immunohistochemical marker yet known for synovial sarcoma [22] . is diagnostic test has since been adopted at multiple institutions worldwide [25] . Importantly, TLE1 is known to function as a transcriptional corepressor in key developmental pathways. us, we began to view the critical function of the SS18-SSX oncoprotein as abnormal transcriptional repression rather than activation, and sought to identify repressed genes within synovial sarcoma gene expression pro les that might be critical to synovial sarcoma oncogenesis. By combining our primary tumor data with published model data [26] , we were able to identify (a tumor suppressor gene with a role in muscle di erentiation) as a direct target of the SS18-SSX oncoprotein [27] . Chromatin immunoprecipitation experiments demonstrated that treatment with HDAC inhibitors reversed SS18-SSX-mediated Polycomb recruitment and epigenetic gene silencing events, restoring expression of . EGR1 then goes on to reactivate expression of the critical PTEN tumor suppressor gene, explaining the connection between synovial sarcoma oncogenesis and this well known cancer pathway for the rst time [28] . Reactivation of appears critical to the mechanism of action of HDAC inhibitors in synovial sarcoma, as siRNA knockdown of abrogates drug-induced apoptosis. us, we nally had a drug that inhibits a direct action of the synovial sarcoma oncoprotein.
Translating the basic science into a clinical trial e lack of e ective systemic therapies for synovial sarcoma, coupled with the completion of phase I and II trials in hematopoetic neoplasms for several HDAC inhibitors, suggested an opportunity to move to human studies without necessarily requiring lengthy animal studies rst to be performed. Synovial sarcomas are rare enough that no single institution will accrue enough cases for a reasonable trial design. Indeed, a major problem in sarcoma medical oncology has been the biologically-inappropriate lumping of all so tissue sarcomas Nielsen. Discovery research to clinical trial: A ten year journey
together into studies, done to increase accrual rates and theoretical statistical power [29] . One compromise is to group only the most biologicallysimilar sarcomas together. Synovial sarcomas are part of a group of mesenchymal malignancies characterized by fusion transcription factor translocations ( Table 1 ). All display a phenotype suggestive of blocked mesenchymal di erentiation, and most present in the extremities of young adults. An evolving body of evidence suggests a role for abnormal transcriptional repression in these diseases [30, 31] ; indeed, as a group they appear highly sensitive to the action of HDAC inhibitors (based on results from our lab [32] and others [33, 34] ).
is work was presented at the NCIC-Clinical Trials Group meetings and caught the attention of the Sarcoma and Investigational New Drug committees. As a result of this attention and in collaboration with medical oncologists uincy Chu and Elizabeth Eisenhauer, we have been able to initiate IND.200, a phase II study of the HDAC inhibitor SB939 in patients with translocation-associated sarcomas. is study has opened at multiple centres across Canada, with the rst patients enrolled in October 2010. In addition to looking for objective response and progression free survival endpoints, correlative science projects embedded in the trial will determine the exact gene translocation present, and test expression of predictive biomarkers using tissue microarrays.
An even faster track to another clinical trial e eld of sarcomas incorporates many "orphan diseases, " and gene expression pro ling data almost certainly contains many other leads worthy of investigation and translation [35] . In the case of the tenosynovial giant cell tumor, the combination of DNA and tissue microarray experiments, initiated in collaboration with Drs. West and van de Rijn from Stanford, led to the implication of aberrant macrophage colony-stimulating factor activity (induced by translocations) as the underlying biological event [36, 37] . is nding immediately implied a potential therapeutic role for CSF1R inhibitors, another emerging drug class under intense development. Indeed, while we were developing preclinical models to test this hypothesis [38] , a group in France jumped straight to "o label" treatment of refractory patients using imatinib (on the basis of its cross-inhibition of CSF1R), inducing at least one dramatic complete response [39] . A trial of the closely-related drug nilotinib began in autumn 2010 in the USA (NCT01207492) and in Europe for patients with relapsed or metastatic tenosynovial giant cell tumor, for which we will provide correlative science support.
Perspectives
By combining clinical knowledge of the problems that need addressing, with research skills on how to employ scienti c tools to e ectively answer these questions, clinician-scientists have the ability, and indeed the responsibility, to take on leadership roles in translational research. In some cases, where the scienti c path is more straight forward, rare diseases may be more worth pursuing than common ones. Regardless, e ective translation requires multidisciplinary collaborations including basic scientists, laboratory and diagnostic physicians, surgical and medical specialists, and statisticians. Actually implementing new advances into practice requires prospective studies that o en need to involve front line physicians, clinical trials groups, industrial collaborators, and health system policy considerations. Microarray research drove many new discovery advances, and a decade later several have reached the point of clinical implementation in prospective studies. We are currently poised on the edge of a similar revolution, based on next generation sequencing technologies [40] . As costs rapidly decrease, medical scientists are gaining the ability to generate not only quantitative data about expression and copy number (in a digital fashion, superior to hybridization-based microarray methods), but also qualitative data about point mutations and other DNA sequence changes that underlie genetic contributions to disease. Generating vast volumes of data is easier than ever before, and the real trick again will be how to make sense of it all. Bioinformatics techniques play a large part, but in health research the ultimate meaning in the data will lie in improvements to patient care. is translational research will be one of the great opportunities and responsibilities for the new generation of clinician-scientists.
